US-based biotechnology company United Therapeutics has signed a definitive merger agreement to buy SteadyMed for a total consideration of $216m, including a $75m contingent.

SteadMed will be paid $4.46 per share in cash at closing and another $2.63 per share upon United Therapeutics reaching a milestone in the commercialisation of Trevyent.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Trevyent is a drug-device combination being developed by SteadyMed as a subcutaneous formulation to treat pulmonary arterial hypertension (PAH).

It integrates the company’s two day, single-use disposable PatchPump with a vasodilatory prostacyclin analogue called treprostinil.

The acquisition is set to complement United Therapeutics’ portfolio aimed at providing therapies for orphan diseases, including PAH.

SteadyMed also works towards the development and commercialisation of drug candidates for orphan and high-value diseases with unmet parenteral delivery needs.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

United Therapeutics chairman and CEO Martine Rothblatt said: “We are optimistic about acquiring SteadyMed and adding Trevyent to our pipeline of products to treat PAH.

“We believe that this proposed acquisition will help us realise our commitment to bring Trevyent to market to improve the lives of patients with PAH.”

“We are especially impressed with SteadyMed’s management team and global supply chain. Trevyent fits in well with our mission, and we look forward to bringing the product to the maximum number of patients as soon as possible.”

SteadyMed president and CEO Jonathan Rigby said: “United Therapeutics has always been at the forefront of developing therapies to treat PAH, and we are delighted at the prospect of our companies coming together, as one, to continue that mission.

“We believe that this proposed acquisition will help us realise our commitment to bring Trevyent to market to improve the lives of patients with PAH.”

The deal is subject to customary closing conditions and is expected to close in the third quarter of this year.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now